Russell J Schilder

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. pmc A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Gynecol Cancer 20:1137-41. 2010
  2. doi request reprint Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:3418-25. 2008
  3. pmc Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Gynecol Oncol 113:21-7. 2009
  4. ncbi request reprint Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 11:5539-48. 2005
  5. ncbi request reprint Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Center, Philadelphia, Pennsylvania 19111, USA
    Gynecol Oncol 88:3-8. 2003
  6. ncbi request reprint Imatinib mesylate and its potential implications for gynecologic cancers
    Holly Dushkin
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Curr Treat Options Oncol 6:115-20. 2005
  7. ncbi request reprint Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis
    Bhavinkumar B Patel
    Division of Basic Science, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer Genomics Proteomics 5:137-49. 2008
  8. doi request reprint A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study
    Lainie P Martin
    Dept of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA Electronic address
    Gynecol Oncol 132:526-30. 2014
  9. ncbi request reprint Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma
    Gloria J Morris
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Haematologica 89:1484-91. 2004
  10. pmc Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Gynecol Oncol 127:70-4. 2012

Detail Information

Publications34

  1. pmc A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Gynecol Cancer 20:1137-41. 2010
    ..Grade 4 nonhematologic toxicity was limited to one patient with anorexia and another with hypomagnesemia. Irofulven administered at this dose and schedule was well tolerated but had modest activity as a single agent...
  2. doi request reprint Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:3418-25. 2008
    ..The association between the expression of certain markers and clinical outcome was investigated...
  3. pmc Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Gynecol Oncol 113:21-7. 2009
    ..Determine if cetuximab dose escalation to induce grade 2 rash correlates with anti-tumor activity and if sera-based markers could predict likelihood of response...
  4. ncbi request reprint Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 11:5539-48. 2005
    ....
  5. ncbi request reprint Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Center, Philadelphia, Pennsylvania 19111, USA
    Gynecol Oncol 88:3-8. 2003
    ....
  6. ncbi request reprint Imatinib mesylate and its potential implications for gynecologic cancers
    Holly Dushkin
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Curr Treat Options Oncol 6:115-20. 2005
    ....
  7. ncbi request reprint Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis
    Bhavinkumar B Patel
    Division of Basic Science, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer Genomics Proteomics 5:137-49. 2008
    ..However, there is limited pre-clinical and clinical data on the molecular targets and action of imatinib in ovarian cancer...
  8. doi request reprint A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study
    Lainie P Martin
    Dept of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA Electronic address
    Gynecol Oncol 132:526-30. 2014
    ....
  9. ncbi request reprint Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma
    Gloria J Morris
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Haematologica 89:1484-91. 2004
    ..We designed a phase II trial of alternating fludarabine and IFNalpha2a to determine response rate, time to progression and toxicity of this regimen in patients with advanced stage low-grade NHL or mantle cell lymphoma...
  10. pmc Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Gynecol Oncol 127:70-4. 2012
    ..The Gynecologic Oncology Group (GOG) conducted a Phase II trial to evaluate the efficacy and safety of dasatinib, an oral SRC-family inhibitor in EOC/PPC, and explored biomarkers for possible association with clinical outcome...
  11. ncbi request reprint Focus on epithelial ovarian cancer
    Robert F Ozols
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Cell 5:19-24. 2004
  12. ncbi request reprint Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma
    Hossein Borghaei
    Fox Chase Cancer Center, Philadelphia, PA, USA
    Clin Lymphoma 5:S16-21. 2004
    ....
  13. pmc A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Gynecol Cancer 19:929-33. 2009
    ....
  14. ncbi request reprint Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer
    Robert E Page
    Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cell Oncol 29:289-99. 2007
    ..We sought to determine if there was an association between the expression of the ubiquitously expressed PCs, furin, PACE-4, PC-5 and PC-7, and ovarian tumor progression...
  15. ncbi request reprint RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model
    Seiji Mabuchi
    Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 13:4261-70. 2007
    ..We examined whether mTOR inhibition by RAD001 (everolimus) is therapeutically efficacious in the treatment of ovarian cancer as a single agent and in combination with cisplatin...
  16. doi request reprint Management of recurrent ovarian carcinoma: current status and future directions
    Lainie P Martin
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Oncol 36:112-25. 2009
    ..This review will discuss the role of chemotherapy in recurrent disease, describe the various agents used in this setting, and touch on the role of biologic agents in recurrent epithelial ovarian carcinoma...
  17. ncbi request reprint Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Invest New Drugs 22:343-9. 2004
    ..This multi-center phase II trial was conducted by the Gynecologic Oncology Group to evaluate the activity and toxicity of irofulven in patients with previously treated adenocarcinoma of the endometrium...
  18. ncbi request reprint Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
    Ursula A Matulonis
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Gynecol Oncol 127:63-9. 2012
    ....
  19. ncbi request reprint Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support
    Meiyu Shen
    Department of Pharacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Chemother Pharmacol 50:243-50. 2002
    ..In addition, single-sample and two-sample limited sampling models (LSMs) were derived to estimate carboplatin's AUC that could be used in the design of drug dosing regimens...
  20. ncbi request reprint Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Gynecol Oncol 96:103-7. 2005
    ..A multicenter study was conducted to evaluate the activity and toxicity of gemcitabine in patients with previously treated non-squamous cell carcinoma of the uterine cervix...
  21. doi request reprint Platinum resistance: the role of DNA repair pathways
    Lainie P Martin
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 14:1291-5. 2008
    ....
  22. ncbi request reprint Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)
    Hossein Borghaei
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Nucl Med 34:4-9. 2004
    ..The ibritumomab tiuxetan regimen is routinely and safely given in an outpatient setting and is completed in 7 to 9 days, and is thus more convenient for patients than chemotherapy...
  23. ncbi request reprint Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects
    Lainie Martin
    From Fox Chase Cancer Center, Philadelphia, Pennsylvania, PA 19103, USA
    J Natl Compr Canc Netw 4:955-66. 2006
    ..This article reviews novel non-cytotoxic agents that target these pathways and are currently being evaluated in ovarian carcinoma treatment...
  24. doi request reprint A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Jason Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 110:140-5. 2008
    ..Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer...
  25. ncbi request reprint Chronic myelogenous leukemia
    Susan O'Brien
    J Natl Compr Canc Netw 3:732-55. 2005
  26. ncbi request reprint Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
    Thomas E Witzig
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:1804-10. 2007
    ..Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined...
  27. ncbi request reprint Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
    Michael S Gordon
    Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
    J Clin Oncol 24:4324-32. 2006
    ..Pertuzumab, a humanized antibody that prevents HER2 dimerization and inhibits multiple HER-mediated pathways, was studied in a phase II, multicenter trial in advanced, refractory OC...
  28. ncbi request reprint Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer Biother Radiopharm 18:165-78. 2003
    ..These correlations were not consistent across the total patient population, and therefore, could not be exploited to predict hematologic toxicity...
  29. ncbi request reprint Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study
    Leo I Gordon
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, 676 N St Clair, Ste 850, Chicago, IL 60611, USA
    Blood 103:4429-31. 2004
    ..Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma...
  30. ncbi request reprint Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature
    Stephen M Ansell
    Division of Hematology Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Clin Lymphoma 5:202-4. 2004
    ....
  31. ncbi request reprint Hodgkin disease/lymphoma
    Richard T Hoppe
    Stanford Comprehensive Cancer Center, USA
    J Natl Compr Canc Netw 6:594-622. 2008
  32. ncbi request reprint Hodgkin disease/lymphoma. Clinical practice guidelines in oncology
    Richard T Hoppe
    J Natl Compr Canc Netw 4:210-30. 2006
  33. ncbi request reprint Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma
    Christos Emmanouilides
    Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA 90095 1678, USA
    Leuk Lymphoma 47:629-36. 2006
    ..The quality of disease remissions obtained when (90)Y ibritumomab tiuxetan is administered after first relapse appears to be comparable with that observed with most chemotherapy regimens in first-relapse patients...
  34. ncbi request reprint Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
    Gregory A Wiseman
    Division of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:4336-42. 2002
    ..The incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 33%, 13%, and 3%, respectively. Reduced-dose ibritumomab tiuxetan is safe and well tolerated and has significant clinical activity in this patient population...